Answers are grounded in this paper and cite their sources.
Glucagon-like peptide-1 (GLP-1) receptor agonists slow kidney disease progression in type 2 diabetes, and in the human kidney the receptor is localized mainly to arteriolar smooth muscle. Whether these cells and their receptor are preserved in diabetic kidney disease (DKD) is unknown. We combined single-cell-level spatial transcriptomics of 5,101 genes with registered periodic acid-Schiff histology in kidney biopsies from 28 people with DKD, 102 with other glomerular diseases and 24 living donors, and measured 2,531 arterioles and small arteries. Arteriolar walls in DKD contained about 20% fewer smooth muscle cells than those in other glomerular diseases, and the loss fell on cells without matrix gene expression. Transcripts of GLP1R, which encodes the receptor, were detected in 0.48% of the remaining smooth muscle cells in DKD, compared with 1.21% in other glomerular diseases and 1.75% in donors. The glutamate receptor gene GRIA2 and the smooth muscle regulator PRDM6 were also lower, whereas contractile genes were unchanged, a pattern not seen in the other diseases. In an independent single-nucleus atlas, smooth muscle GLP1R was lower in DKD than in reference kidneys, and smooth muscle content fell with arteriolar hyalinosis grade. In human DKD, arterioles lose contractile smooth muscle cells, and fewer of the remaining cells carry transcripts for the receptor targeted by GLP-1 receptor agonists at the disease stage in which these drugs are used.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: